{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:20:33Z","timestamp":1716398433196},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"DOI":"10.7759\/cureus.45680","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:06:56Z","timestamp":1695298016000},"source":"Crossref","is-referenced-by-count":1,"title":["Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis"],"prefix":"10.7759","author":[{"given":"Salman","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayyab","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mishal","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Updated Recommendations on Treatment of Adolescents and Children With Chronic HCV Infection. Policy Brief. (2022). Accessed: August 19, 2023: https:\/\/www.who.int\/publications\/i\/item\/9789240052710."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-90","article-title":"Prevalence, determinants, and management of chronic kidney disease in Karachi, Pakistan - a community based cross-sectional study","volume":"15","author":"Jessani S","year":"2014","unstructured":"Jessani S, Bux R, Jafar TH. Prevalence, determinants, and management of chronic kidney disease in Karachi, Pakistan - a community based cross-sectional study. BMC Nephrol. 2014, 15:90. 10.1186\/1471-2369-15-90","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5702","article-title":"Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the sofosbuvir and daclatasvir regimen","volume":"11","author":"Butt N","year":"2019","unstructured":"Butt N, Abbasi A, Ali Khan M, Ali M, Mahesar GB, Haleem F, Manan A. Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the sofosbuvir and daclatasvir regimen. Cureus. 2019, 11:e5702. 10.7759\/cureus.5702","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.101017","article-title":"Hepatitis C and treatment in patients with chronic kidney disease","volume":"67","author":"Jalota A","year":"2021","unstructured":"Jalota A, Lindner BK, Thomas B, Lerma EV. Hepatitis C and treatment in patients with chronic kidney disease. Dis Mon. 2021, 67:101017. 10.1016\/j.disamonth.2020.101017","journal-title":"Dis Mon"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.14003","article-title":"Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy","volume":"27","author":"Toyoda H","year":"2023","unstructured":"Toyoda H, Kikuchi K. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy. Ther Apher Dial. 2023, 27:831-8. 10.1111\/1744-9987.14003","journal-title":"Ther Apher Dial"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou GN","year":"2019","unstructured":"Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?. Gastroenterology. 2019, 156:446-460.e2. 10.1053\/j.gastro.2018.10.033","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13810","article-title":"Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan","volume":"52","author":"Takehara T","year":"2022","unstructured":"Takehara T, Izumi N, Mochida S, et al.. Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan. Hepatol Res. 2022, 52:833-40. 10.1111\/hepr.13810","journal-title":"Hepatol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia SM","year":"2019","unstructured":"Borgia SM, Dearden J, Yoshida EM, et al.. Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019, 71:660-5. 10.1016\/j.jhep.2019.05.028","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus LI","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011, 9:509-516.e1. 10.1016\/j.cgh.2011.03.004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01636-7","article-title":"Guidelines have a key role in driving HCV elimination by advocating for simple HCV care pathways","volume":"38","author":"Mangia A","year":"2021","unstructured":"Mangia A, Albanese AP, Bourli\u00e9re M, et al.. Guidelines have a key role in driving HCV elimination by advocating for simple HCV care pathways. Adv Ther. 2021, 38:1397-403. 10.1007\/s12325-021-01636-7","journal-title":"Adv Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul M","year":"2019","unstructured":"Jadoul M, Bieber BA, Martin P, et al.. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019, 95:939-47. 10.1016\/j.kint.2018.11.038","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232931","article-title":"The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis","volume":"15","author":"Akhtar S","year":"2020","unstructured":"Akhtar S, Nasir JA, Usman M, Sarwar A, Majeed R, Billah B. The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis. PLoS One. 2020, 15:e0232931. 10.1371\/journal.pone.0232931","journal-title":"PLoS One"},{"key":"ref13","article-title":"Risk factors for hepatitis C virus infection in patients on long-term hemodialysis","volume":"15","author":"Khokhar N","year":"2005","unstructured":"Khokhar N, Alam AY, Naz F, Mahmud SN. Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. J Coll Physicians Surg Pak. 2005, 15:326-8.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1776111","article-title":"Hepatitis c virus and chronic kidney disease","volume":"14","author":"Khan MU","year":"2020","unstructured":"Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol. 2020, 14:579-90. 10.1080\/17474124.2020.1776111","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 Clinical Practice Guideline for\u00a0the\u00a0Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"8","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","year":"2018","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Hepatitis C Work Group: KDIGO 2018 Clinical Practice Guideline for\u00a0the\u00a0Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011). 2018, 8:91-165. 10.1016\/j.kisu.2018.06.001","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"Calvaruso V","year":"2020","unstructured":"Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020, 73:1548-56. 10.1016\/j.jhep.2020.08.006","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.202","article-title":"Hepatitis C virus infection in chronic kidney disease: Paradigm shift in management","volume":"33","author":"Kim SM","year":"2018","unstructured":"Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: Paradigm shift in management. Korean J Intern Med. 2018, 33:670-8. 10.3904\/kjim.2018.202","journal-title":"Korean J Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.11.008","article-title":"A systematic review of direct-acting antivirals for hepatitis C in advanced CKD","volume":"8","author":"Balk EM","year":"2023","unstructured":"Balk EM, Adam GP, Jadoul M, Martin P, Gordon CE. A systematic review of direct-acting antivirals for hepatitis C in advanced CKD. Kidney Int Rep. 2023, 8:240-53. 10.1016\/j.ekir.2022.11.008","journal-title":"Kidney Int Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619840149","article-title":"Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges","volume":"7","author":"Ekpanyapong S","year":"2019","unstructured":"Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J. 2019, 7:642-50. 10.1177\/2050640619840149","journal-title":"United European Gastroenterol J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.252","article-title":"Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: A Phase 3b study","volume":"38","author":"Heo J","year":"2023","unstructured":"Heo J, Kim YJ, Lee SW, et al.. Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: A Phase 3b study. Korean J Intern Med. 2023, 38:504-13. 10.3904\/kjim.2022.252","journal-title":"Korean J Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/aid2.13336","article-title":"Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir\u2010velpatasvir","author":"Su PK","year":"2022","unstructured":"Su PK, Chang TS, Tung SY, et al.. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir\u2010velpatasvir. Adv Dig Med. 2022, 10.1002\/aid2.13336","journal-title":"Adv Dig Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.037","article-title":"Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: A large cohort study from the Nationwide HCV Registry Program (TACR)","volume":"20","author":"Huang CF","year":"2022","unstructured":"Huang CF, Tseng KC, Cheng PN, et al.. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: A large cohort study from the Nationwide HCV Registry Program (TACR). Clin Gastroenterol Hepatol. 2022, 20:1151-1162.e6. 10.1016\/j.cgh.2021.07.037","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon P","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, et al.. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017, 152:142-156.e2. 10.1053\/j.gastro.2016.09.009","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01837-y","article-title":"Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan","volume":"21","author":"Huang YT","year":"2021","unstructured":"Huang YT, Hsieh YY, Chen WM, et al.. Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol. 2021, 21:259. 10.1186\/s12876-021-01837-y","journal-title":"BMC Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3\u00a0infection\u00a0and cirrhosis","volume":"155","author":"Esteban R","year":"2018","unstructured":"Esteban R, Pineda JA, Calleja JL, et al.. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3\u00a0infection\u00a0and cirrhosis. Gastroenterology. 2018, 155:1120-7.e4. 10.1053\/j.gastro.2018.06.042","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3758744","article-title":"Utilization of HCV viremic kidneys with genotyping\/subtyping-free sofosbuvir\/velpatasvir treatment strategy: Experience from China","volume":"2022","author":"Zhang H","year":"2022","unstructured":"Zhang H, Liu Q, Hu S, et al.. Utilization of HCV viremic kidneys with genotyping\/subtyping-free sofosbuvir\/velpatasvir treatment strategy: Experience from China. Biomed Res Int. 2022, 2022:3758744. 10.1155\/2022\/3758744","journal-title":"Biomed Res Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023384","article-title":"Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C","volume":"99","author":"Li C","year":"2020","unstructured":"Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore). 2020, 99:e23384. 10.1097\/MD.0000000000023384","journal-title":"Medicine (Baltimore)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.933313","article-title":"Sofosbuvir\/velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors","volume":"26","author":"Chen R","year":"2021","unstructured":"Chen R, Li D, Zhang M, Yuan X. Sofosbuvir\/velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors. Ann Transplant. 2021, 26:e933313. 10.12659\/AOT.933313","journal-title":"Ann Transplant"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa187","article-title":"Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir","volume":"36","author":"Goel A","year":"2021","unstructured":"Goel A, Bhadauria DS, Kaul A, et al.. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant. 2021, 36:1867-71. 10.1093\/ndt\/gfaa187","journal-title":"Nephrol Dial Transplant"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab072","article-title":"Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease","volume":"37","author":"Sise ME","year":"2022","unstructured":"Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant. 2022, 37:2327-34. 10.1093\/ndt\/gfab072","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/179204-sofosbuvir-and-velpatasvir-regimen-outcome-for-chronic-hepatitis-c-patients-with-end-stage-renal-disease-undergoing-hemodialysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:51Z","timestamp":1707509271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/179204-sofosbuvir-and-velpatasvir-regimen-outcome-for-chronic-hepatitis-c-patients-with-end-stage-renal-disease-undergoing-hemodialysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.45680","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}